Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
about
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityDiagnosis and therapy of non-variceal upper gastrointestinal bleedingPiroxicam-β-cyclodextrin: a GI safer piroxicam25 Years of Proton Pump Inhibitors: A Comprehensive Review.Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?Drug-induced side effects affecting the gastrointestinal tractEffect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulantsMaintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studiesGastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defenceA prospective study of aspirin use and the risk of gastrointestinal bleeding in menAspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users.NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression.Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety.Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota.Non-steroidal Anti-inflammatory Drugs (NSAIDs) Use in Primary Health Care Centers in A'Seeb, Muscat: A Clinical Audit.Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.The gastroprotective effect of pogostone from Pogostemonis Herba against indomethacin-induced gastric ulcer in rats.Treatment and chemoprevention of NSAID-associated gastrointestinal complications.Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazoleCost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis.Esomeprazole: a proton pump inhibitor.The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.The pharmacology of esomeprazole and its role in gastric acid related diseases.Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategiesSafety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease.Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.Managing the adverse effects of nonsteroidal anti-inflammatory drugs.Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database.Current pharmacotherapy options for gastritis.
P2860
Q22306448-093FF24E-424C-4BDD-B905-2BDA00CBEB94Q24615651-4F4CBC63-F870-463F-AB84-878B07ED98C7Q26777626-869A8140-5CCE-46B7-AFE7-605E236F2F15Q27023475-09005809-C7FF-457D-9EF4-9AD7EA7204AAQ28070003-1B33D6F2-0E24-4B01-9699-3B8FEA68AD7BQ28201393-56D4987C-DBCE-41F5-ADFE-0C4030309F1FQ28219073-E848925D-E407-4A51-A5CF-6E994B80C482Q28219972-F4FBF4CC-F922-4D87-840C-6BA5CEA3520AQ28221704-8240D46E-C192-46CC-B5CD-5BE5B46245F3Q28482202-0178300F-4411-465F-9EB7-6D06AF70D565Q28743884-64BA3C38-E634-4F9F-A5DC-8D9E49B6005BQ30457290-52F550B1-C70A-470A-9A68-17A846EE736FQ31034785-34ED06D4-9AD0-49B1-8E16-C26D8945C88CQ33701847-C06E764F-FEB5-40A6-A000-B85F4A00A630Q34636475-ADFDC9B5-AB1B-4061-A5AB-9FA09DC37C7BQ34807370-8482975B-1826-460D-B9D2-F6AD2A643D49Q35314338-033F3197-FA10-49CF-B1F2-202C08185F28Q36076845-35968AEA-B874-4456-BE04-C98B7EA98B12Q36174087-C5866FD3-9011-4720-B756-5056086F2906Q36332697-82A09A50-E306-4A6A-ACBC-3465F59200EAQ36808048-9415C2D8-150B-4AE7-899C-4E95BC7BFCA4Q36844540-80AC8543-0FFF-42ED-959B-0C013BEBAF2AQ37071499-6CE81615-BFA8-4EF5-8674-AD24387CB033Q37230285-D0AD5436-4593-4C45-BF8F-4B960E18185DQ37260543-96976D59-604A-45D7-BE1D-81A55298CDB9Q37272199-BD6EC626-52DE-40C4-996D-442764604328Q37358250-D7FBEAEF-3433-4919-B1C0-D7D43013A0FCQ37363371-B953D943-5306-4427-B0B3-DC4E565FC67BQ37390644-87533612-C0FC-43B3-9F27-16B01312337DQ37475646-3C211A26-0471-4201-B6F3-59B8A0F9DB74Q37552951-C47CE85F-C903-4BE2-AE5C-0B98AA9A0C5FQ37808208-5D952A34-FBB4-4000-BCA0-7513F34F8E15Q37882741-CAA572D0-BC3E-40B5-AC9D-6E9FE67B40BBQ37900840-F1AB1B43-328E-420E-B59C-03DD6D9726B5Q37903846-8EFB16C5-67AC-45FD-A139-64E5B78FD54CQ37960540-65F98960-AB71-497D-859F-C4144B3D5502Q37986562-E5599BC7-D40E-45C1-A6F5-454143DB7EA2Q37994187-23A2E239-2C89-4549-A8EB-121718EBFA33Q38041462-EFC324EF-55F6-4B6D-82A8-991F8A2B517BQ38061147-DD3F3949-09CD-4C5C-97D9-52D923E59AA0
P2860
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@en
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@nl
type
label
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@en
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@nl
prefLabel
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@en
Prevention of ulcers by esomep ...... e NSAIDs and COX-2 inhibitors.
@nl
P2093
P2860
P1476
Prevention of ulcers by esomep ...... ve NSAIDs and COX-2 inhibitors
@en
P2093
Christopher Hawkey
Dariusz Kleczkowski
Henrik Ahlbom
James M Scheiman
Jorge L Rainoldi
Jørgen Naesdal
Kjell-Arne Ung
Leszek Szczepanski
Nicholas J Talley
Nimish Vakil
P2860
P304
P356
10.1111/J.1572-0241.2006.00499.X
P407
P577
2006-02-22T00:00:00Z